These are treacherous times for the pharmaceutical and medical device industries as legislators have recently added new laws to the regulatory mix, and prosecutors, both here and abroad, have vowed to step up enforcement. Join us for a webinar as three Ballard Spahr attorneys—all former federal prosecutors—discuss how to minimize risks in times of escalating scrutiny.
The Foreign Corrupt Practices Act was already a major concern for companies in the life sciences sector because of their extensive interaction with foreign government officials on matters such as licensing, regulatory approvals, and contracting. Now the Dodd-Frank Act has increased those risks with newly enacted whistleblower provisions that promise potentially huge rewards to complainants. And the SEC has established an independent Office of the Whistleblower to do nothing but handle whistleblower tips and complaints.
On the other side of the Atlantic, the UK Bribery Act 2010—perhaps the most stringent anti-bribery legislation in the world—went into effect in July, and prosecutors there recently launched a whistleblower hotline.
In this webinar, we will discuss how these important developments will reverberate in the life sciences industry, exploring these topics:
- Recent FCPA enforcement actions in the life sciences sector
- Theories of liability under the FCPA
- How the Dodd-Frank whistleblower provisions may change the enforcement landscape
- How the UK Bribery Act affects global compliance issues
- Important red flags to be aware of
- What compliance adjustments or additional procedures should be considered
12:00 PM - 1:00 PM PT | Webinar
3:00 PM - 4:00 PM ET | Webinar
Thomas W. McNamara, Partner, White Collar/Investigations
Henry E. Hockeimer, Jr., Partner, White Collar/Investigations
Samuel W. Cantrell, Associate, White Collar/Investigations
Jonathan S. Satinsky, Associate, White Collar/Investigations